{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:12:27Z","timestamp":1760015547223,"version":"build-2065373602"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Epidermolysis bullosa (EB) comprises a heterogeneous group of rare, genetic blistering diseases. The wide variety in EB trial outcomes limits the comparability of outcomes and, consequently, the implementation of the best available treatment options. A core outcome set (COS) is a minimum set of outcomes that should be measured in all clinical trials, comprising <jats:italic>what<\/jats:italic> should be measured (i.e., outcome domains) and <jats:italic>how<\/jats:italic> it should be measured (i.e., outcome measurement instruments). This enables standardization of outcome measurement aiming at improving the comparability and quality of research.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The Core Outcome Set for Epidermolysis Bullosa (COSEB) initiative aims to develop COSs for use in clinical trials for the four major EB types: EB simplex, junctional EB, dystrophic EB, and Kindler EB. This protocol focuses on the development of core outcome domain sets \u2014 outlining <jats:italic>what<\/jats:italic> should be measured in EB clinical trials. Involved stakeholders are patients and patient representatives, clinicians, researchers, methodologists, industry representatives, regulators, health technology assessors, and payers. In the initial part, working groups are formed to define long lists of candidate outcome domains for the four major EB types. Potentially relevant outcome domains will be identified based on scoping literature reviews and qualitative studies. Following consultations with a stakeholder advisory panel, a short list of candidate outcome domains will be subject to voting in Delphi consensus procedures. Finally, the definitive core outcome domain sets for the four major EB types and, if indicated, any overarching core outcome domain sets, will be confirmed in consensus meetings. The project Has been prospectively registered in the COMET registry for COSs on 23 October 2017 (registration number 1033).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>This protocol provides guidance to ensure a systematic, transparent, and comprehensible approach of COSEB. The final core outcome domain sets are supposed to serve as the minimum sets of <jats:italic>what<\/jats:italic> to measure in future EB trials. This will provide the basis for the subsequent outcome measurement instrument selection. Particularly in this rare disease with inherently small-sized study cohorts, this will facilitate the incorporation of meaningful outcomes and pooling of data, ultimately enhancing optimal treatment for EB.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>This study Has been prospectively registered in the COMET database on 23 October 2017 and updated on 24 January 2022 (registration number 1033 <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.comet-initiative.org\/studies\/details\/1033\" ext-link-type=\"uri\">https:\/\/www.comet-initiative.org\/studies\/details\/1033<\/jats:ext-link>).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13063-025-09052-w","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:35:11Z","timestamp":1760013311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Core outcome domain sets for clinical trials in epidermolysis bullosa \u2014 a COSEB protocol to achieve consensus on \u201cwhat\u201d to measure"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9166-5654","authenticated-orcid":false,"given":"Eva W. H.","family":"Korte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3734-753X","authenticated-orcid":false,"given":"Peter C.","family":"van den Akker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2331-8981","authenticated-orcid":false,"given":"Dimitra","family":"Kiritsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0750-3818","authenticated-orcid":false,"given":"Jan","family":"Kottner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0641-3829","authenticated-orcid":false,"given":"Anna M. G.","family":"Pasmooij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0956-3788","authenticated-orcid":false,"given":"Cecilia A. C.","family":"Prinsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8705-3890","authenticated-orcid":false,"given":"Verena","family":"Wally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3159-0720","authenticated-orcid":false,"given":"Tobias","family":"Welponer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6035-2863","authenticated-orcid":false,"given":"Phyllis I.","family":"Spuls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6932-0374","authenticated-orcid":false,"given":"Martin","family":"Laimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-9363","authenticated-orcid":false,"given":"Maria C.","family":"Bolling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the COSEB Consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"9052_CR1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","volume":"183","author":"C Has","year":"2020","unstructured":"Has C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183:614\u201327. https:\/\/doi.org\/10.1111\/bjd.18921.","journal-title":"Br J Dermatol"},{"key":"9052_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0210-0","volume":"6","author":"A Bardhan","year":"2020","unstructured":"Bardhan A, Bruckner-Tuderman L, Chapple ILC, et al. Epidermolysis bullosa. Nat Rev Dis Primers. 2020;6: 78. https:\/\/doi.org\/10.1038\/s41572-020-0210-0.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"9052_CR3","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/jdv.18637","volume":"37","author":"C Has","year":"2023","unstructured":"Has C, Hess M, Anemuller W, et al. Epidemiology of inherited epidermolysis bullosa in Germany. J Eur Acad Dermatol Venereol. 2023;37(2):402\u201310. https:\/\/doi.org\/10.1111\/jdv.18637.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9052_CR4","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/jdv.17012","volume":"35","author":"R Baardman","year":"2021","unstructured":"Baardman R, Yenamandra VK, Duipmans JC. Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB registry: EB more common than previously assumed? J Eur Acad Dermatol Venereol. 2021;35:995\u20131006. https:\/\/doi.org\/10.1111\/jdv.17012.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9052_CR5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/bjd.20958","volume":"186","author":"G Petrof","year":"2022","unstructured":"Petrof G, Papanikolaou M, Martinez AE, et al. The epidemiology of epidermolysis bullosa in England and Wales: data from the national epidermolysis bullosa database. Br J Dermatol. 2022;186:843\u20138. https:\/\/doi.org\/10.1111\/bjd.20958.","journal-title":"Br J Dermatol"},{"key":"9052_CR6","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamadermatol.2016.2473","volume":"152","author":"JD Fine","year":"2016","unstructured":"Fine JD. Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the National Epidermolysis Bullosa Registry. JAMA Dermatol. 2016;152:1231\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2016.2473.","journal-title":"JAMA Dermatol"},{"key":"9052_CR7","doi-asserted-by":"publisher","unstructured":"Fine JD and Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. J Am Acad Dermatol 2009; 61: 367\u2013384; quiz 385\u2013366. https:\/\/doi.org\/10.1016\/j.jaad.2009.03.052.","DOI":"10.1016\/j.jaad.2009.03.052"},{"key":"9052_CR8","doi-asserted-by":"publisher","unstructured":"Fine JD and Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol 2009; 61: 387\u2013402; quiz 403\u2013384. https:\/\/doi.org\/10.1016\/j.jaad.2009.03.053.","DOI":"10.1016\/j.jaad.2009.03.053"},{"key":"9052_CR9","doi-asserted-by":"publisher","first-page":"C896","DOI":"10.1152\/ajpcell.00117.2022","volume":"323","author":"M Palamenghi","year":"2022","unstructured":"Palamenghi M, De Luca M, De Rosa L. The steep uphill path leading to ex vivo gene therapy for genodermatoses. Am J Physiol Cell Physiol. 2022;323:C896\u2013906. https:\/\/doi.org\/10.1152\/ajpcell.00117.2022.","journal-title":"Am J Physiol Cell Physiol"},{"key":"9052_CR10","doi-asserted-by":"publisher","unstructured":"Kocher T, Petkovic I, Bischof J, et al. Current developments in gene therapy for epidermolysis bullosa. Expert Opin Biol Ther 2022: 1\u201314. 20220314. https:\/\/doi.org\/10.1080\/14712598.2022.2049229.","DOI":"10.1080\/14712598.2022.2049229"},{"key":"9052_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.matbio.2022.04.007","volume":"110","author":"N Harvey","year":"2022","unstructured":"Harvey N, Youssefian L, Saeidian AH, et al. Pathomechanisms of epidermolysis bullosa: beyond structural proteins. Matrix Biol. 2022;110:91\u2013105. https:\/\/doi.org\/10.1016\/j.matbio.2022.04.007.","journal-title":"Matrix Biol"},{"key":"9052_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/bjd\/ljad077","volume":"189","author":"EWH Korte","year":"2023","unstructured":"Korte EWH, Welponer T, Kottner J, et al. Heterogeneity of reported outcomes in epidermolysis bullosa clinical research: a scoping review as a first step towards outcome harmonization. Br J Dermatol. 2023;189:80\u201390. https:\/\/doi.org\/10.1093\/bjd\/ljad077.","journal-title":"Br J Dermatol"},{"key":"9052_CR13","doi-asserted-by":"publisher","unstructured":"Loh CC, Kim J, Su JC, et al. Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). J Am Acad Dermatol 2014; 70: 89\u201397 e81\u201313. 2013\/12\/21. https:\/\/doi.org\/10.1016\/j.jaad.2013.09.041.","DOI":"10.1016\/j.jaad.2013.09.041"},{"issue":"1","key":"9052_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0739-5","volume":"12","author":"JW Frew","year":"2017","unstructured":"Frew JW, Davidson M, Murrell DF. Disease-specific health related quality of life patient reported outcome measures in genodermatoses: a systematic review and critical evaluation. Orphanet J Rare Dis. 2017;12(1): 189. https:\/\/doi.org\/10.1186\/s13023-017-0739-5.","journal-title":"Orphanet J Rare Dis"},{"key":"9052_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-1978-4","volume":"18","author":"PR Williamson","year":"2017","unstructured":"Williamson PR, Altman DG, Bagley H, et al. The COMET handbook: version 1.0. Trials. 2017;18: 280. https:\/\/doi.org\/10.1186\/s13063-017-1978-4.","journal-title":"Trials"},{"issue":"2","key":"9052_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/bjd\/ljad361","volume":"190","author":"EWH Korte","year":"2024","unstructured":"Korte EWH, Spuls PI, van den Akker PC, et al. Harmonization of outcomes in epidermolysis bullosa: report of the core outcome sets for epidermolysis bullosa (COSEB) kick-off meeting. Br J Dermatol. 2024;190(2):268\u201370. https:\/\/doi.org\/10.1093\/bjd\/ljad361.","journal-title":"Br J Dermatol"},{"key":"9052_CR17","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1001\/jama.2022.21022","volume":"328","author":"NJ Butcher","year":"2022","unstructured":"Butcher NJ, Monsour A, Mew EJ, et al. Guidelines for reporting outcomes in trial reports: the CONSORT-outcomes 2022 extension. JAMA. 2022;328:2252\u201364. https:\/\/doi.org\/10.1001\/jama.2022.21022.","journal-title":"JAMA"},{"key":"9052_CR18","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1001\/jama.2022.21243","volume":"328","author":"NJ Butcher","year":"2022","unstructured":"Butcher NJ, Monsour A, Mew EJ, et al. Guidelines for reporting outcomes in trial protocols: the SPIRIT-outcomes 2022 extension. JAMA. 2022;328:2345\u201356. https:\/\/doi.org\/10.1001\/jama.2022.21243.","journal-title":"JAMA"},{"key":"9052_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2024.111277","volume":"169","author":"IJ Saldanha","year":"2024","unstructured":"Saldanha IJ, Hughes KL, Dodd S, et al. Study found increasing use of core outcome sets in Cochrane systematic reviews and identified facilitators and barriers. J Clin Epidemiol. 2024;169: 111277. https:\/\/doi.org\/10.1016\/j.jclinepi.2024.111277.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"9052_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/bjd.16273","volume":"178","author":"CAC Prinsen","year":"2018","unstructured":"Prinsen CAC, Spuls PI, Terwee CB. By using a core outcome set we measure what matters to patients. Br J Dermatol. 2018;178(3):579\u201380. https:\/\/doi.org\/10.1111\/bjd.16273.","journal-title":"Br J Dermatol"},{"issue":"1","key":"9052_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/jid.2014.320","volume":"135","author":"J Schmitt","year":"2015","unstructured":"Schmitt J, Apfelbacher C, Spuls PI, et al. The harmonizing outcome measures for eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology. J Invest Dermatol. 2015;135(1):24\u201330. https:\/\/doi.org\/10.1038\/jid.2014.320.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"9052_CR22","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/j.jaad.2022.04.042","volume":"87","author":"A Garg","year":"2022","unstructured":"Garg A, Dirr MA, Jemec GBE, et al. Shifting focus from \u201cwhat we do\u201d to the \u201cimpact of what we do\u201d: application of outcome measures to routine clinical care in dermatology. J Am Acad Dermatol. 2022;87(2):e83\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2022.04.042.","journal-title":"J Am Acad Dermatol"},{"key":"9052_CR23","unstructured":"COSEB registration COMET."},{"key":"9052_CR24","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/bjd\/ljad278","volume":"189","author":"YA Leshem","year":"2023","unstructured":"Leshem YA, Simpson EL, Apfelbacher C, et al. The harmonising outcome measures for eczema (HOME) implementation roadmap. Br J Dermatol. 2023;189:710\u20138. https:\/\/doi.org\/10.1093\/bjd\/ljad278.","journal-title":"Br J Dermatol"},{"key":"9052_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152438","volume":"66","author":"B Shea","year":"2024","unstructured":"Shea B, Pardo JP, Grosskleg S, et al. Increasing uptake through collaboration in the development of core outcome sets: lessons learned at OMERACT 2023. Semin Arthritis Rheum. 2024;66: 152438. https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152438.","journal-title":"Semin Arthritis Rheum"},{"issue":"983\u2013988","key":"9052_CR26","doi-asserted-by":"publisher","first-page":"20221028","DOI":"10.1007\/s00403-022-02424-1","volume":"315","author":"J Rick","year":"2023","unstructured":"Rick J, Gould LJ, Marzano AV, et al. The \u201cUnderstanding Pyoderma Gangrenosum, Review and Assessment of Disease Effects (UPGRADE) Project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosum. Arch Dermatol Res. 2023;315(983\u2013988):20221028. https:\/\/doi.org\/10.1007\/s00403-022-02424-1.","journal-title":"Arch Dermatol Res"},{"key":"9052_CR27","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1111\/jdv.16429","volume":"34","author":"H R\u00f6nsch","year":"2020","unstructured":"R\u00f6nsch H, Apfelbacher C, Brans R, et al. Protocol for the development of a core domain set for hand eczema trials. J Eur Acad Dermatol Venereol. 2020;34:2871\u20136. https:\/\/doi.org\/10.1111\/jdv.16429.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9052_CR28","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.16672","volume":"179","author":"L Thorlacius","year":"2018","unstructured":"Thorlacius L, Ingram JR, Villumsen B, et al. A core domain set for hidradenitis suppurativa trial outcomes: an international delphi process. Br J Dermatol. 2018;179:642\u201350. https:\/\/doi.org\/10.1111\/bjd.16672.","journal-title":"Br J Dermatol"},{"key":"9052_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad397","author":"L Fertitta","year":"2023","unstructured":"Fertitta L, Bergqvist C, Sarin K, et al. A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials. Br J Dermatol. 2023. https:\/\/doi.org\/10.1093\/bjd\/ljad397.","journal-title":"Br J Dermatol"},{"key":"9052_CR30","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1111\/jdv.17376","volume":"35","author":"GB Langbroek","year":"2021","unstructured":"Langbroek GB, Wolkerstorfer A, Horbach SER, et al. Development of a core outcome domain set for clinical research on capillary malformations (the COSCAM project). J Eur Acad Dermatol Venereol. 2021;35:1888\u201395. https:\/\/doi.org\/10.1111\/jdv.17376.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9052_CR31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/bjd.21741","volume":"187","author":"A Lechner","year":"2022","unstructured":"Lechner A, Coleman S, Balzer K, et al. Core outcomes for pressure ulcer prevention trials: results of an international consensus study. Br J Dermatol. 2022;187:743\u201352. https:\/\/doi.org\/10.1111\/bjd.21741.","journal-title":"Br J Dermatol"},{"key":"9052_CR32","doi-asserted-by":"publisher","unstructured":"Rossel VSVJ, Shourick J, Bolling MC, et al. Protocol for the development of a Core Outcome Set for Inherited Ichthyosis (COSII). Dermatology 2025: 1\u201312. https:\/\/doi.org\/10.1159\/000546035.","DOI":"10.1159\/000546035"},{"issue":"1","key":"9052_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3230-x","volume":"20","author":"JJ Kirkham","year":"2019","unstructured":"Kirkham JJ, Gorst S, Altman DG, et al. Core outcome set-STAndardised protocol items: the cos-stap statement. Trials. 2019;20(1): 116. https:\/\/doi.org\/10.1186\/s13063-019-3230-x.","journal-title":"Trials"},{"issue":"1","key":"9052_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-016-1555-2","volume":"17","author":"CA Prinsen","year":"2016","unstructured":"Prinsen CA, Vohra S, Rose MR, et al. How to select outcome measurement instruments for outcomes included in a \u201ccore outcome set\u201d - a practical guideline. Trials. 2016;17(1): 449. https:\/\/doi.org\/10.1186\/s13063-016-1555-2.","journal-title":"Trials"},{"key":"9052_CR35","unstructured":"Harmonizing Outcome Measures for Eczema (HOME) website., http:\/\/www.homeforeczema.org\/."},{"key":"9052_CR36","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/bjd.16812","volume":"179","author":"J Kottner","year":"2018","unstructured":"Kottner J, Schmitt J. Core outcome sets in dermatology: next steps. Br J Dermatol. 2018;179:549\u201350. https:\/\/doi.org\/10.1111\/bjd.16812.","journal-title":"Br J Dermatol"},{"key":"9052_CR37","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1056\/nejmsa1012065","volume":"364","author":"DA Zarin","year":"2011","unstructured":"Zarin DA, Tse T, Williams RJ, et al. The clinicaltrials.gov results database \u2014 update and key issues. N Engl J Med. 2011;364:852\u201360. https:\/\/doi.org\/10.1056\/nejmsa1012065.","journal-title":"N Engl J Med"},{"key":"9052_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2024.111307","volume":"169","author":"J Kottner","year":"2024","unstructured":"Kottner J, Beaton D, Clarke M, et al. Core outcome set developers should consider and specify the level of granularity of outcome domains. J Clin Epidemiol. 2024;169: 111307. https:\/\/doi.org\/10.1016\/j.jclinepi.2024.111307.","journal-title":"J Clin Epidemiol"},{"key":"9052_CR39","unstructured":"EB Clinet Expert Database., https:\/\/www.eb-clinet.org\/our-network\/eb-clinet-contacts-a-z\/ (accessed April 24, 2024)."},{"key":"9052_CR40","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/bjd\/ljae200","volume":"191","author":"EWH Korte","year":"2024","unstructured":"Korte EWH, Pasmooij AMG, Bolling MC, et al. Towards a roadmap for COSEB: the next steps in harmonization of outcomes for epidermolysis bullosa. Br J Dermatol. 2024;191:463\u20135. https:\/\/doi.org\/10.1093\/bjd\/ljae200.","journal-title":"Br J Dermatol"},{"key":"9052_CR41","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02107-2022","volume":"61","author":"AG Mathioudakis","year":"2023","unstructured":"Mathioudakis AG, Khaleva E, Fally M, et al. Core outcome sets, developed collaboratively with patients, can improve the relevance and comparability of clinical trials. Eur Respir J. 2023;61: 20230403. https:\/\/doi.org\/10.1183\/13993003.02107-2022.","journal-title":"Eur Respir J"},{"key":"9052_CR42","unstructured":"COMET PoPPIE Working Group, https:\/\/comet-initiative.org\/Patients\/POPPIE."},{"key":"9052_CR43","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1177\/104973239300300403","volume":"3","author":"ME Fonteyn","year":"1993","unstructured":"Fonteyn ME, Kuipers B, Grobe SJ. A description of think aloud method and protocol analysis. Qual Health Res. 1993;3:430\u201341. https:\/\/doi.org\/10.1177\/104973239300300403.","journal-title":"Qual Health Res"},{"key":"9052_CR44","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/jdv.18923","volume":"37","author":"H R\u00f6nsch","year":"2023","unstructured":"R\u00f6nsch H, Schiffers F, Ofenloch R, et al. Which outcomes should be measured in hand eczema trials? Results from patient interviews and an expert survey. J Eur Acad Dermatol Venereol. 2023;37:1199\u2013206. https:\/\/doi.org\/10.1111\/jdv.18923.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"9052_CR45","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/bjd.19694","volume":"185","author":"W Oei","year":"2021","unstructured":"Oei W, Fledderus AC, Spuls PI, et al. Development of an international core domain set for medium, large and giant congenital melanocytic naevi as a first step towards a core outcome set for clinical practice and research. Br J Dermatol. 2021;185(2):371\u20139. https:\/\/doi.org\/10.1111\/bjd.19694.","journal-title":"Br J Dermatol"},{"key":"9052_CR46","unstructured":"C3 Core Outcome Set Development Checklist."},{"key":"9052_CR47","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/bjd.20437","volume":"185","author":"AC Fledderus","year":"2021","unstructured":"Fledderus AC, Pasmans S, Wolkerstorfer A, et al. Domains and outcomes of the core outcome set of congenital melanocytic naevi for clinical practice and research (the OCOMEN project): part 2. Br J Dermatol. 2021;185:970\u20137. https:\/\/doi.org\/10.1111\/bjd.20437.","journal-title":"Br J Dermatol"},{"key":"9052_CR48","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jclinepi.2018.12.010","volume":"108","author":"E Gargon","year":"2019","unstructured":"Gargon E, Crew R, Burnside G, et al. Higher number of items associated with significantly lower response rates in COS Delphi surveys. J Clin Epidemiol. 2019;108:110\u201320. https:\/\/doi.org\/10.1016\/j.jclinepi.2018.12.010.","journal-title":"J Clin Epidemiol"},{"key":"9052_CR49","first-page":"29","volume":"7","author":"N Jairath","year":"1994","unstructured":"Jairath N, Weinstein J. The Delphi methodology (part one): a useful administrative approach. Can J Nurs Adm. 1994;7:29\u201342.","journal-title":"Can J Nurs Adm"},{"key":"9052_CR50","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1177\/0269216317690685","volume":"31","author":"S J\u00fcnger","year":"2017","unstructured":"J\u00fcnger S, Payne SA, Brine J, et al. Guidance on conducting and reporting DElphi studies (CREDES) in palliative care: recommendations based on a methodological systematic review. Palliat Med. 2017;31:684\u2013706. https:\/\/doi.org\/10.1177\/0269216317690685.","journal-title":"Palliat Med"},{"key":"9052_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2024.111485","volume":"174","author":"AM Manyara","year":"2024","unstructured":"Manyara AM, Purvis A, Ciani O, et al. Sample size in multistakeholder Delphi surveys: at what minimum sample size do replicability of results stabilize? J Clin Epidemiol. 2024;174: 111485. https:\/\/doi.org\/10.1016\/j.jclinepi.2024.111485.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"9052_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-016-1479-x","volume":"17","author":"ST Brookes","year":"2016","unstructured":"Brookes ST, Macefield RC, Williamson PR, et al. Three nested randomized controlled trials of peer-only or multiple stakeholder group feedback within Delphi surveys during core outcome and information set development. Trials. 2016;17(1): 409. https:\/\/doi.org\/10.1186\/s13063-016-1479-x.","journal-title":"Trials"},{"key":"9052_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-2405-6","volume":"19","author":"ST Brookes","year":"2018","unstructured":"Brookes ST, Chalmers KA, Avery KNL, et al. Impact of question order on prioritisation of outcomes in the development of a core outcome set: a randomised controlled trial. Trials. 2018;19: 66. https:\/\/doi.org\/10.1186\/s13063-017-2405-6.","journal-title":"Trials"},{"issue":"10","key":"9052_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002148","volume":"13","author":"JJ Kirkham","year":"2016","unstructured":"Kirkham JJ, Gorst S, Altman DG, et al. Core outcome set-STAndards for reporting: the COS-STAR statement. PLoS Med. 2016;13(10): e1002148. https:\/\/doi.org\/10.1371\/journal.pmed.1002148.","journal-title":"PLoS Med"},{"key":"9052_CR55","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","volume":"67","author":"IR Diamond","year":"2014","unstructured":"Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of delphi studies. J Clin Epidemiol. 2014;67:401\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.12.002.","journal-title":"J Clin Epidemiol"},{"key":"9052_CR56","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jclinepi.2019.03.011","volume":"111","author":"D De Meyer","year":"2019","unstructured":"De Meyer D, Kottner J, Beele H, et al. Delphi procedure in core outcome set development: rating scale and consensus criteria determined outcome selection. J Clin Epidemiol. 2019;111:23\u201331. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.03.011.","journal-title":"J Clin Epidemiol"},{"key":"9052_CR57","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","volume":"27","author":"CAC Prinsen","year":"2018","unstructured":"Prinsen CAC, Mokkink LB, Bouter LM, et al. Cosmin guideline for systematic reviews of patient-reported outcome measures. Qual Life Res. 2018;27:1147\u201357. https:\/\/doi.org\/10.1007\/s11136-018-1798-3.","journal-title":"Qual Life Res"},{"key":"9052_CR58","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s11136-017-1765-4","volume":"27","author":"LB Mokkink","year":"2018","unstructured":"Mokkink LB, de Vet HCW, Prinsen CAC, et al. Cosmin risk of bias checklist for systematic reviews of patient-reported outcome measures. Qual Life Res. 2018;27:1171\u20139. https:\/\/doi.org\/10.1007\/s11136-017-1765-4.","journal-title":"Qual Life Res"},{"issue":"8","key":"9052_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027473","volume":"9","author":"A Nygaard","year":"2019","unstructured":"Nygaard A, Halvorsrud L, Linnerud S, et al. The James Lind Alliance process approach: scoping review. BMJ Open. 2019;9(8): e027473. https:\/\/doi.org\/10.1136\/bmjopen-2018-027473.","journal-title":"BMJ Open"},{"key":"9052_CR60","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1007\/s00403-023-02729-9","volume":"315","author":"OM Haddadin","year":"2023","unstructured":"Haddadin OM, Jacobson ME, Chen DM, et al. Minimum data set for treatment effectiveness in pyoderma gangrenosum (MIDSTEP): an international protocol of an e-Delphi study to develop a clinical physician-driven treatment effectiveness registry on behalf of the UPGRADE initiative. Arch Dermatol Res. 2023;315:2913\u20139. https:\/\/doi.org\/10.1007\/s00403-023-02729-9.","journal-title":"Arch Dermatol Res"},{"key":"9052_CR61","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/bjd\/ljad454","volume":"190","author":"HE Wainman","year":"2024","unstructured":"Wainman HE, Chandran NS, Frew JW, et al. Global consensus process to establish a core dataset for hidradenitis suppurativa registries. Br J Dermatol. 2024;190:510\u20138. https:\/\/doi.org\/10.1093\/bjd\/ljad454.","journal-title":"Br J Dermatol"},{"key":"9052_CR62","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/s41390-020-01119-5","volume":"89","author":"SE Damhuis","year":"2021","unstructured":"Damhuis SE, Bloomfield FH, Khalil A, et al. A core outcome set and minimum reporting set for intervention studies in growth restriction in the NEwbOrN: the cosneon study. Pediatr Res. 2021;89:1380\u20135. https:\/\/doi.org\/10.1038\/s41390-020-01119-5.","journal-title":"Pediatr Res"},{"key":"9052_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3588-9","author":"M Knol","year":"2019","unstructured":"Knol M, Wang H, Bloomfield F, et al. Development of a core outcome set and minimum reporting set for intervention studies in growth restriction in the NEwbOrN (COSNEON): study protocol for a Delphi study. Trials. 2019. https:\/\/doi.org\/10.1186\/s13063-019-3588-9.","journal-title":"Trials"},{"key":"9052_CR64","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/s0140-6736(25)00672-5","volume":"405","author":"S Hopewell","year":"2025","unstructured":"Hopewell S, Chan A-W, Collins GS, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. Lancet. 2025;405:1633\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(25)00672-5.","journal-title":"Lancet"},{"key":"9052_CR65","doi-asserted-by":"publisher","first-page":"g1687","DOI":"10.1136\/bmj.g1687","volume":"348","author":"TC Hoffmann","year":"2014","unstructured":"Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDier) checklist and guide. BMJ. 2014;348:g1687\u2013g1687. https:\/\/doi.org\/10.1136\/bmj.g1687.","journal-title":"BMJ"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09052-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09052-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09052-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:35:14Z","timestamp":1760013314000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09052-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9052"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09052-w","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The central Ethics Review Board non-WMO studies of the University Medical Center Groningen (CTc UMCG) has approved the current study (METc 2024\/475). The data protection officer at each participating center will be involved. Written informed consent will be obtained from patients participating in the qualitative studies. Informed consent for the participants in the Delphi survey is unnecessary; however, all participants will need to express their willingness to participate and their consent to use of their data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"E. K., P. A., A. P., J. K., C. P., T. W., and M. L. declare that they have no competing interests. D. K. has served as a consultant for Amryt Pharma, Fibrx Inc., and RHEACELL GmbH and is co-founder of Crowd Pharma, a company focusing on repurposing losartan for EB. V. W. acts as consultant for and holds shares of Diaderm GmbH. P. S. receives departmental independent research grants for TREAT NL registry from Pharma since December 2019; is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of, e.g., psoriasis and atopic dermatitis, for which financial compensation is paid to the department\/hospital; and is chief investigator (CI) of the systemic and phototherapy atopic eczema registry (TREAT NL) for adults and children. She participated in the development of one of the HOME core outcome instruments (Recap of atopic eczema (RECAP)) and in the development of the Outcome Measures for VAscular Malformations (OVAMA) questionnaire for vascular malformations. M. B. has served in the Advisory Boards of Amryt Pharma and Krystal Biotech Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"399"}}